Menu

SIMDAX® (i.v. levosimendan)

SIMDAX® (i.v. levosimendan) is an inodilator (calcium sensitizer and potassium channel opener) indicated for the short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate.

If you are a healthcare professional, you can register as a user in the section for healthcare professionals for full information on SIMDAX®.

Prescribing information

SIMDAX® is indicated for the short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate. Read more.

Register here

Our section for healthcare professionals provides additional and useful information, including several videos, on SIMDAX®. Join us and register HERE. 


1. Nieminen MS et al. Eur Heart J Suppl. 2017;19(suppl C);C15-C21
2. Papp Z et al. Int J Cardiol. 2012;159:82–87.

Read more


WEBCASTS

Next live event will take place on March 21st 2018 from ISICEM congress
Follow this page for updates of next webcasts and info about on-demand viewing of the past events.


Acute and Advanced Heart Failure Knowledge Center »
 


Levosimendan in Wikipedia »


LeodorTrial logo image file
Repetitive Levosimendan infusions for patients with advanced chronic heart failure »

Blog on Acute and Advanced Heart Failure

Prof Pölzl's blog about therapeutic options for Acute and Advanced Heart Failure »

Prof G Pölzl 

Heart Failure Matters: Website for HF patients, their families and carers

 heart failure matters logo

Heartfailurematters.org is an educational website available in 9 languages, developed by cardiologists, nurses, primary care physicians and patients from the Heart Failure Association of the ESC.

It highlights lifestyle adjustments that enable patients with heart failure to maintain their quality-of-life.

Visit Heart Failure Matters